Literature DB >> 16030164

Two polymorphisms in the glucocorticoid receptor gene directly affect glucocorticoid-regulated gene expression.

Henk Russcher1, Pauline Smit, Erica L T van den Akker, Elisabeth F C van Rossum, Albert O Brinkmann, Frank H de Jong, Steven W J Lamberts, Jan W Koper.   

Abstract

CONTEXT: Interindividual variation in glucocorticoid (GC)-sensitivity can be partly explained by polymorphisms in the GC receptor (GR) gene. The ER22/23EK and N363S polymorphisms have been described to be associated with lower and higher GC sensitivity, respectively. OBJECTIVE AND
DESIGN: We examined the basis of this altered GC sensitivity by expressing GR(N363S) and GR(ER22/23EK) in COS-1 cells and investigating their transactivating and transrepressing capacities using a GC response element-luciferase reporter and a p65-activated nuclear factor kappaB-luciferase reporter, respectively. Furthermore, we evaluated the transactivating and transrepressing capacities of the GR in peripheral blood mononuclear lymphocytes of homozygous and heterozygous carriers of these polymorphisms by determining the maximum effect of dexamethasone on transactivation of the GC-induced leucine-zipper and transinhibition of the IL-2 gene by means of real-time RT-PCR.
RESULTS: The effects of the polymorphisms in the GR gene previously observed in population studies were also detected at the level of gene expression. The ER22/23EK polymorphism resulted in a significant reduction of transactivating capacity, in both transfection experiments (-14 +/- 5%, P < 0.05) and peripheral blood mononuclear lymphocytes of carriers of this polymorphism (homozygous: -48 +/- 6%, P < 0.01, n = 1; heterozygous: -21 +/- 4%, P = 0.08, n = 3). The N363S polymorphism, associated with increased GC sensitivity, resulted in a significantly increased transactivating capacity, both in vitro (8 +/- 3%; P < 0.02) and ex vivo (homozygous: 204 +/- 19%, P < 0.0001, n = 1; heterozygous: 124 +/- 8%, P = 0.05, n = 3). Neither the ER22/23EK nor the N363S polymorphism seemed to influence the transrepressing capacity of the GR.
CONCLUSION: The presence of these and other GC sensitivity-modulating polymorphisms may have consequences for the use of GCs in a clinical setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16030164     DOI: 10.1210/jc.2005-0646

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  47 in total

Review 1.  Glucocorticoid-induced osteonecrosis.

Authors:  Robert S Weinstein
Journal:  Endocrine       Date:  2011-12-15       Impact factor: 3.633

2.  Molecular evidence for a link between the N363S glucocorticoid receptor polymorphism and altered gene expression.

Authors:  Christine M Jewell; John A Cidlowski
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

3.  A functional SNP in the NKX2.5-binding site of ITPR3 promoter is associated with susceptibility to systemic lupus erythematosus in Japanese population.

Authors:  Tetsuya Oishi; Aritoshi Iida; Shigeru Otsubo; Yoichiro Kamatani; Masayuki Usami; Takashi Takei; Keiko Uchida; Ken Tsuchiya; Susumu Saito; Yozo Ohnisi; Katsushi Tokunaga; Kosaku Nitta; Yasushi Kawaguchi; Naoyuki Kamatani; Yuta Kochi; Kenichi Shimane; Kazuhiko Yamamoto; Yusuke Nakamura; Wako Yumura; Koichi Matsuda
Journal:  J Hum Genet       Date:  2008-01-25       Impact factor: 3.172

4.  The NR3C1 Glucocorticoid Receptor Gene Polymorphisms May Modulate the TGF-beta mRNA Expression in Asthma Patients.

Authors:  Michał Panek; Tadeusz Pietras; Artur Fabijan; Jan Zioło; Łukasz Wieteska; Beata Małachowska; Wojciech Fendler; Janusz Szemraj; Piotr Kuna
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

Review 5.  Tissue-specific glucocorticoid action: a family affair.

Authors:  Katherine L Gross; John A Cidlowski
Journal:  Trends Endocrinol Metab       Date:  2008-09-19       Impact factor: 12.015

Review 6.  Glucocorticoid-induced osteoporosis and osteonecrosis.

Authors:  Robert S Weinstein
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-23       Impact factor: 4.741

Review 7.  Molecular mechanism of glucocorticoid resistance in inflammatory bowel disease.

Authors:  Sara De Iudicibus; Raffaella Franca; Stefano Martelossi; Alessandro Ventura; Giuliana Decorti
Journal:  World J Gastroenterol       Date:  2011-03-07       Impact factor: 5.742

Review 8.  Pathogenesis of glucocorticoid-induced osteoporosis and options for treatment.

Authors:  Pojchong Chotiyarnwong; Eugene V McCloskey
Journal:  Nat Rev Endocrinol       Date:  2020-04-14       Impact factor: 43.330

9.  Genetic evidence for the association of the hypothalamic-pituitary-adrenal (HPA) axis with ADHD and methylphenidate treatment response.

Authors:  Marie-Ève Fortier; Sarojini M Sengupta; Natalie Grizenko; Zia Choudhry; Geeta Thakur; Ridha Joober
Journal:  Neuromolecular Med       Date:  2012-10-10       Impact factor: 3.843

10.  The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy.

Authors:  Viktória Szabó; Gábor Borgulya; Tamás Filkorn; Judit Majnik; Ilona Bányász; Zoltán Zsolt Nagy
Journal:  Mol Vis       Date:  2007-04-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.